Search Results - "McDermott, Cara L"

Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis by McDermott, Cara L, Lockhart, Catherine M, Devine, Beth

“…Objective:  We conducted a meta-analysis of randomised studies that assessed the effectiveness of directly observed hepatitis C medication therapy delivered in…”
Get full text

Utilization patterns and characteristics of users of biologic anti‐inflammatory agents in a large, US commercially insured population by Mendelsohn, Aaron B., Nam, Young Hee, Marshall, James, McDermott, Cara L., Kochar, Bharati, Kappelman, Michael D., Brown, Jeffrey S., Lockhart, Catherine M.

“…We report utilization patterns and characteristics of patients treated with biologic anti‐inflammatory agents in a large commercially insured patient…”
Get full text

Risk Assessment and Prevention of Falls in Older Community-Dwelling Adults: A Review by Colón-Emeric, Cathleen S, McDermott, Cara L, Lee, Deborah S, Berry, Sarah D

“…IMPORTANCE: Falls are reported by more than 14 million US adults aged 65 years or older annually and can result in substantial morbidity, mortality, and health…”
Get full text

Complementary and alternative medicine use among newly diagnosed prostate cancer patients by McDermott, Cara L., Blough, David K., Fedorenko, Catherine R., Arora, Neeraj K., Zeliadt, Steven B., Fairweather, Megan E., Oakley-Girvan, Ingrid, Van Den Eeden, Stephen K., Ramsey, Scott D.

“…Purpose We surveyed prostate cancer patients about complementary and alternative medicine (CAM) use and evaluated patient factors that correlated with CAM use…”
Get full text

Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials by Bennette, Caroline S, Ramsey, Scott D, McDermott, Cara L, Carlson, Josh J, Basu, Anirban, Veenstra, David L

“…The extent to which trial-level factors differentially influence accrual to trials has not been comprehensively studied. Our objective was to evaluate the…”
Get full text

Depression and Health Care Utilization at End of Life Among Older Adults With Advanced Non–Small-Cell Lung Cancer by McDermott, Cara L., Bansal, Aasthaa, Ramsey, Scott D., Lyman, Gary H., Sullivan, Sean D.

“…Limited data exist regarding how depression diagnosed at different times relative to a cancer diagnosis may affect healthcare utilization at end of life (EOL)…”
Get full text

Factors Associated With Hospital Admission in the Last Month: A Retrospective Single Center Analysis by Ma, Jessica E., Olsen, Maren K., McDermott, Cara L., Bowling, C. Barrett, Hastings, S. Nicole, White, Tyler, Casarett, David

“…Driven by concerns about care quality, patient experience, and national metrics, health systems are increasingly focusing on identifying risk factors for…”
Get full text

Criteria for Enrollment of Patients With COPD in Palliative Care Trials: A Systematic Review by Smirnova, Natalia, Lange, Allison V., Glickman, Amanda, Desanto, Kristen, McDermott, Cara L., Sullivan, Donald R., Bekelman, David B., Kavalieratos, Dio

“…Use of palliative care interventions in chronic obstructive pulmonary disease (COPD) has increased in recent years and inclusion criteria used to identify…”
Get full text

The landscape of real-world evidence of rituximab utilization and clinical outcomes in patients with cancer, rheumatoid arthritis, and multiple sclerosis: A scoping review by Li, Kevin H, Kaker, Mohammad, Lau, Jerry, Noonan, Kyle, Zhang, Stephanie, McDermott, Cara L, Lockhart, Catherine M

“…Rituximab (RTX) is an anti-CD20 monoclonal antibody that is used to treat various conditions in cancer, rheumatoid arthritis (RA), and multiple sclerosis (MS)…”
Get full text

Effect of the COVID-19 Pandemic on Place of Death Among Medicaid and Commercially Insured Patients With Cancer in Washington State by Panattoni, Laura E, McDermott, Cara L, Li, Li, Sun, Qin, Fedorenko, Catherine R, Sanchez, Hayley A, Kreizenbeck, Karma L, Shankaran, Veena, Ramsey, Scott D

“…The COVID-19 pandemic-related disruptions in health care delivery might have affected end-of-life care in patients with cancer. We examined changes in place of…”
Get full text

Authors' Response to: Novel Data Linkage for Quality Improvement in Palliative and End-of-Life Care by McDermott, Cara L., Engelberg, Ruth A., Curtis, J. Randall

Get full text

Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States by Rai, Ashish, Nam, Young Hee, Mendelsohn, Aaron B, Marshall, James, McDermott, Cara L, Toh, Sengwee, Lockhart, Catherine M

“…The first follow-on drug (Basaglar) of the originator insulin glargine (Lantus), a long-acting insulin for treatment of type 1 and type 2 diabetes mellitus…”
Get full text

Novel Data Linkages to Characterize Palliative and End-Of-Life Care: Challenges and Considerations by McDermott, Cara L., Engelberg, Ruth A., Woo, Cossette, Li, Li, Fedorenko, Catherine, Ramsey, Scott D., Curtis, J. Randall

“…Working groups have called for linkages of existing and diverse databases to improve quality measurement in palliative and end-of-life (EOL) care, but limited…”
Get full text

Advance Care Planning Documentation and Intensity of Care at the End of Life for Adults With Congestive Heart Failure, Chronic Kidney Disease, and Both Illnesses by Bernacki, Gwen M., McDermott, Cara L., Matlock, Daniel D., O'Hare, Ann M., Brumback, Lyndia, Bansal, Nisha, Kirkpatrick, James N., Engelberg, Ruth A., Curtis, Jared Randall

“…Heart failure (HF) and chronic kidney disease (CKD) are associated with high morbidity and mortality, especially in combination, yet little is known about the…”
Get full text

Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States by Mai, Xiaodan, Mendelsohn, Aaron B, Marshall, James, Lin, Nancy D, McDermott, Cara L, Ko, Jenice S, Pawloski, Pamala A, Jamal-Allial, Aziza, Daniels, Kimberly, McMahill-Walraven, Cheryl N, Djibo, Djeneba Audrey, Lockhart, Catherine M

“…Trastuzumab is an antihuman epidermal growth factor receptor 2 monoclonal antibody used to treat breast and other cancers. Trastuzumab biosimilars were…”
Get full text

What Does it Mean to be an Excellent Mentor? J. Randall "Randy" Curtis' Living Legacy by McDermott, Cara L, Coats, Heather, Bernacki, Gwen M, Blakeney, Erin Abu-Rish, Brown, Crystal E, Lau, Nancy, Lee, Robert Y, Modes, Matthew E, Steineck, Angela, Steiner, Jill M, Taylor, Mallory R, Kross, Erin K

Get full text

Pragmatic methods to avoid intensive care unit admission when it does not align with patient and family goals by Khandelwal, Nita, Long, Ann C, Lee, Robert Y, McDermott, Cara L, Engelberg, Ruth A, Curtis, J Randall

“…For patients with chronic, life-limiting illnesses, admission to the intensive care unit (ICU) near the end of life might not improve patient outcomes or be…”
Get full text

Pharmacologic Management of Agitation in Patients with Dementia by McDermott, Cara L., Gruenewald, David A.

“…Purpose of Review Agitation is common among older adults with dementia; its origin may be multi-factorial, and it is often difficult to treat. In this paper,…”
Get full text

Barriers and facilitators to conduct high‐quality, large‐scale safety and comparative effectiveness research: The Biologics and Biosimilars Collective Intelligence Consortium experience by Lockhart, Catherine M., McDermott, Cara L., Felix, Thomas, Lin, Nancy D., Cziraky, Mark J., Mendelsohn, Aaron B., Brown, Jeffrey S.

Get full text

Fall Risk and Medication Use Near End of Life Among Adults With Chronic Obstructive Pulmonary Disease by McDermott, Cara L, Feemster, Laura C, Engelberg, Ruth A, Spece, Laura J, Donovan, Lucas M, Curtis, J Randall

“…Falls are frequent among people with chronic obstructive pulmonary disease (COPD) and associated with increased morbidity, mortality, and healthcare costs…”
Get full text